Diagnostic and prognostic value of <i>FOXD1</i> expression in head and neck squamous cell carcinoma

Qiu, Shijie; Li, Dan; Shen, Zhisen; Li, Qun; Shen, Yi; Deng, Hongxia; Wu, Yidong; Zhou, Chongchang

doi:10.7150/jca.47978

Cited by 11 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with LSCC from the TCGA were separated into the high‐ ITGA5 and the low‐ ITGA5 groups according to their median value. The Gene Set Enrichment Analysis (GSEA, version 4.1.0) was performed in our previous study 16 …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma

Zhou

Wei

Shen

et al. 2022

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Background Integrin α5 (ITGA5) was involved in a variety of cancers. However, the role of ITGA5 in laryngeal squamous cell carcinoma (LSCC) remains unknown. Methods The expression of ITGA5 and the corresponding clinicopathological parameters of LSCC patients the TCGA database. Five datasets (GSE51985, GSE59102, GSE84957, GSE27020, and GSE65858) were downloaded from the GEO database as validation sets. Kaplan–Meier plotter, Cox regression analysis, and nomogram were performed to determine the prognostic value of ITGA5 in LSCC. GO, KEGG, and GSEA were used to explore the underlying biological functions of ITGA5 in LSCC. The algorithms ESTIMATE and CIBERSORT were adopted to evaluate the association between ITGA5 and the infiltration of the immune cells. The algorithm pRRophetic was used to estimate the response to chemotherapeutic drugs. Results The expression of ITGA5 was higher in the LSCC samples and linked to poor overall survival and recurrence‐free survival. Further, the Cox regression analysis confirmed that high expression of ITGA5 was an independent unfavorable prognostic factor. The predictive performance of nomogram based on the expression of ITGA5 was accurate and practical. The functional enrichment analysis confirmed that ITGA5 was related to the construction of the components and structures of the extracellular matrix. Finally, patients with high ITGA5 expression were more likely to benefit from docetaxel and gemcitabine. Conclusion The expression of ITGA5 was elevated in the LSCC and was a predictor for prognosis and chemotherapeutic response in LSCC patients.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The Gene Set Enrichment Analysis (GSEA, version 4.1.0) was performed in our previous study. 16 The c2.cp.kegg.v7.2.symbols.gmt was utilized as reference gene sets. Pathways with false discovery rate (FDR) p < 0.05 were considered statistically enriched.…”

Section: Methodsmentioning

confidence: 99%

ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma

Zhou

Wei

Shen

et al. 2022

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

show abstract

“…FOXD1 is highly expressed in HNSCC and is a good diagnostic biomarker for patients with HNSCC (Qiu et al, 2021). More importantly, FOXD1 has been found to be upregulated in OSCC associated with unfavorable prognosis (Li, Yan, et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

FOXD1‐AS1 upregulates FOXD1 to promote oral squamous cell carcinoma progression

Han

Luo

2021

Oral Diseases

View full text Add to dashboard Cite

Objectives Recently, increasing attention has been concentrated on decrypting the potential of long non‐coding RNAs (lncRNAs) in influencing the progression of human tumors, oral squamous cell carcinoma (OSCC) included. The role of a novel lncRNA, forkhead box D1 antisense RNA 1 (FOXD1‐AS1), has been discussed in multiple cancers. Nevertheless, its function and relevant mechanism in OSCC have been not probed yet. Materials and methods FOXD1‐AS1 expression was detected via RT‐qPCR. Colony formation, EdU, transwell and Western blot analyses tested the functional role of FOXD1‐AS1 in OSCC cells. The relationship between RNAs was assessed by a series of mechanical assays. Results FOXD1‐AS1 was expressed at a high level in head and neck squamous cell carcinoma (HNSC). Knockdown of FOXD1‐AS1 exerted repressive impacts on OSCC cell proliferation, migration, invasion, and EMT. Moreover, FOXD1‐AS1 positively regulated its nearby gene FOXD1 via interacting with miR‐369‐3p. In addition, adenosine deaminase RNA specific (ADAR), known as a RNA‐binding protein (RBP), was capable to bind with FOXD1‐AS1 and FOXD1 simultaneously, and could regulate the stability of FOXD1 mRNA. Aside from that, rescue assays delineated that FOXD1‐AS1 promoted OSCC progression via upregulating FOXD1. Conclusions FOXD1‐AS1 elevates FOXD1 expression to promote OSCC malignant phenotypes through miR‐369‐3p and ADAR.

show abstract

“…The practical steps for total RNA synthesis and quantitative reverse transcription-polymerase chain reaction (qRT–PCR) are outlined in our previous study [ 22 ]. The primer sequences for CD3D are shown below: 5’-ACTGGCTACCCTTCTCTCG-3’ (forward primer) and 5’-CCGTTCCCTCTACCCATGTGA-3’ (reverse primer).…”

Section: Methodsmentioning

confidence: 99%

“…Based on these DEGs, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed utilizing the org.Hs.e.d package. Gene set enrichment analysis (GSEA, version 4.1.0) was utilized in functional enrichment analysis as previously described [ 22 ].…”

Section: Methodsmentioning

confidence: 99%

CD3D: a prognostic biomarker associated with immune infiltration and immunotherapeutic response in head and neck squamous cell carcinoma

et al. 2022

Self Cite

View full text Add to dashboard Cite

Recent studies have demonstrated that CD3D activates T-cell-related signal transduction and is associated with the antitumor immune response in several cancers. This study explored the role of CD3D in head and neck squamous cell carcinoma (HNSCC). A total of 499 HNSCC tissues and 44 normal controls were acquired from The Cancer Genome Atlas as the training cohort. GSE65858 included 270 HNSCC patients and was obtained from the Gene Expression Omnibus database as the test cohort. Overall, 172 HNSCC patients were collected as the validation cohort. CD3D expression in the validation cohort was measured by quantitative real-time polymerase chain reaction. The Kaplan–Meier plot revealed that high CD3D expression was associated with longer overall survival in HNSCC patients. Univariate and multivariate analyses showed that CD3D expression was an independent prognostic factor for HNSCC patients, which was confirmed in the test cohort and validation cohort. Furthermore, GO, KEGG, and GSEA analyses revealed the association of CD3D with immune-related pathways. Subsequently, ESTIMATE analysis showed the association between CD3D and the tumor microenvironment, while ssGSEA showed a remarkable positive link between CD3D and immune-related functions. Multiple algorithms demonstrated that high CD3D expression was associated with more immune effector cell infiltration. Finally, the tumor immune dysfunction and exclusion (TIDE) score and immunophenoscore (IPS) showed that patients with high CD3D could benefit from immunotherapy. In summary, CD3D was an independent favorable prognostic biomarker and correlated with immune cell infiltration and immune-related function, as well as an efficient indicator of immunotherapy response for HNSCC patients.

show abstract

Diagnostic and prognostic value of FOXD1 expression in head and neck squamous cell carcinoma

Cited by 11 publications

References 40 publications

ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma

ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma

FOXD1‐AS1 upregulates FOXD1 to promote oral squamous cell carcinoma progression

CD3D: a prognostic biomarker associated with immune infiltration and immunotherapeutic response in head and neck squamous cell carcinoma

Contact Info

Product

Resources

About